Company intelligence / Profile preview
Lyell Immunopharma
South San Francisco, California, USAlyell.com ↗
- Ownership
- Public · LYEL
- Employees
- ~500
- Development stage
- Phase 1
01
Overview
Lyell Immunopharma is advancing a pipeline of next-generation CAR T-cell therapies. Recent clinical data from the Phase 1/2 trial of LYL314 (formerly IMPT-314) for large B-cell lymphoma showed promising results with high rates of durable complete responses.
- Therapeutic areas
- Oncology
- Modalities
- CAR T-cell therapies
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Outpace Bio
04
Financials
- Market cap
- $367.6M
- Total revenue
- $36K
- Enterprise value
- $224.8M
Beyond the preview
Go deeper on Lyell Immunopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lyell Immunopharma.